Related references
Note: Only part of the references are listed.Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma
I. Borbath et al.
EUROPEAN JOURNAL OF CANCER (2012)
Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors
Jesper B. Andersen et al.
GASTROENTEROLOGY (2012)
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
Jeeyun Lee et al.
LANCET ONCOLOGY (2012)
Thrombotic Microangiopathy with Targeted Cancer Agents
John A. Blake-Haskins et al.
CLINICAL CANCER RESEARCH (2011)
Genetics of Biliary Tract Cancers and Emerging Targeted Therapies
Aram F. Hezel et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Best Supportive Care Compared With Chemotherapy for Unresectable Gall Bladder Cancer: A Randomized Controlled Study
Atul Sharma et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study
Birgit Gruenberger et al.
LANCET ONCOLOGY (2010)
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
Andrew X. Zhu et al.
LANCET ONCOLOGY (2010)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma
F Leone et al.
CLINICAL CANCER RESEARCH (2006)
Liver transplantation for unresectable perihilar cholangiocarcinoma
JK Heimbach et al.
SEMINARS IN LIVER DISEASE (2004)
Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?
YH Shaib et al.
JOURNAL OF HEPATOLOGY (2004)
Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma:: a GERCOR study
T André et al.
ANNALS OF ONCOLOGY (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Cholangiocarcinoma: Current concepts and insights
GJ Gores
HEPATOLOGY (2003)
Changing international trends in mortality rates for liver, biliary and pancreatic tumours
SA Khan et al.
JOURNAL OF HEPATOLOGY (2002)
Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma
WR Jarnagin et al.
ANNALS OF SURGERY (2001)
Frequency of p16INK4A alterations and k-ras mutations in intrahepatic cholangiocarcinoma of the liver
A Tannapfel et al.
GUT (2000)
Share Paper
